Potential Effects of Silymarin and Its Flavonolignan Components in Patients with β-Thalassemia Major: A Comprehensive Review in 2015 (Q26753151)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26997953 AND SRC:MED&resulttype=core&format=json

12 March 2020

title

Potential Effects of Silymarin and Its Flavonolignan Components in Patients with β-Thalassemia Major: A Comprehensive Review in 2015 (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26997953 AND SRC:MED&resulttype=core&format=json

12 March 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26997953 AND SRC:MED&resulttype=core&format=json

12 March 2020

Ebrahim Salehifar

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26997953 AND SRC:MED&resulttype=core&format=json

12 March 2020

author name string

Mehrnoush Kosaryan

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26997953 AND SRC:MED&resulttype=core&format=json

12 March 2020

Aily Aliasgharian

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26997953 AND SRC:MED&resulttype=core&format=json

12 March 2020

Hossein Jalali

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26997953 AND SRC:MED&resulttype=core&format=json

12 March 2020

Arash Hadian Amree

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26997953 AND SRC:MED&resulttype=core&format=json

12 March 2020

language of work or name

English

0 references

publication date

21 February 2016

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26997953 AND SRC:MED&resulttype=core&format=json

Advances in Pharmacological Sciences

12 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26997953 AND SRC:MED&resulttype=core&format=json

12 March 2020

volume

2016

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26997953 AND SRC:MED&resulttype=core&format=json

12 March 2020

page(s)

3046373

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26997953 AND SRC:MED&resulttype=core&format=json

Creative Commons Attribution 4.0 International

12 March 2020

copyright license

start time

1 January 2016

1 reference

April 2022 Public Data File from Crossref

Creative Commons Attribution 4.0 International

0 references

copyright status

copyrighted

1 reference

April 2022 Public Data File from Crossref

cites work

Identification of hepatoprotective flavonolignans from silymarin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4779508

Multitargeted therapy of cancer by silymarin

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4779508

Ineffective erythropoiesis in β -thalassemia

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4779508

Silymarin inhibits in vitro T-cell proliferation and cytokine production in hepatitis C virus infection

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4779508

A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4779508

Therapeutic value of combined therapy with deferiprone and silymarin as iron chelators in Egyptian children with beta thalassemia major

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4779508

Evaluating the safety and efficacy of silymarin in β-thalassemia patients: a review

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4779508

Bone density in transfusion dependent thalassemia patients in Urmia, Iran

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4779508

Estrogen receptors alpha (ERα) and beta (ERβ): subtype-selective ligands and clinical potential.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4779508

Association of Iron Overload with Oxidative Stress, Hepatic Damage and Dyslipidemia in Transfusion-Dependent β-Thalassemia/HbE Patients

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4779508

Silymarin and its constituents in cardiac preconditioning.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4779508

Silibinin inhibits the production of pro-inflammatory cytokines through inhibition of NF-κB signaling pathway in HMC-1 human mast cells

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4779508

Protective Role of Silymarin and Deferoxamine Against Iron Dextran-induced Renal Iron Deposition in Male Rats

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4779508

Silymarin inhibits cell cycle progression and mTOR activity in activated human T cells: therapeutic implications for autoimmune diseases

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4779508

Silibinin inhibits prostate cancer cells- and RANKL-induced osteoclastogenesis by targeting NFATc1, NF-κB, and AP-1 activation in RAW264.7 cells

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4779508

Effect of silymarin (milk thistle) on liver disease in patients with chronic hepatitis C unsuccessfully treated with interferon therapy: a randomized controlled trial

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4779508

Silymarin selectively protects human renal cells from cisplatin-induced cell death

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4779508

Silibinin induces apoptosis via calpain-dependent AIF nuclear translocation in U87MG human glioma cell death

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4779508

The iron-chelating potential of silybin in patients with hereditary haemochromatosis

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4779508

Silymarin suppress CD4 T cell activation and proliferation: effects on NF-kappaB activity and IL-2 production.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4779508

Silibinin protects OTA-mediated TNF-alpha release from perfused rat livers and isolated rat Kupffer cells

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4779508

Effects of silymarin on hepatitis C virus and haem oxygenase-1 gene expression in human hepatoma cells

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4779508

Toward the definition of the mechanism of action of silymarin: activities related to cellular protection from toxic damage induced by chemotherapy

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4779508

Effects of silymarin on the spontaneous proliferation and cell cycle of human peripheral blood leukemia T cells

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4779508

The use of selected nutrition supplements and complementary and alternative medicine in liver disease

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4779508

Pathogenetic aspects of immune deficiency associated with beta-thalassemia

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4779508

Flavonoid antioxidant silymarin and skin cancer

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4779508

Iron and immunity: a double-edged sword.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4779508

Effects of iron overload on the immune system

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4779508

Co-Administration of Silymarin and Deferoxamine against Kidney, Liver and Heart Iron Deposition in Male Iron Overload Rat Model

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4779508

Therapeutic value of combined therapy with deferasirox and silymarin on iron overload in children with Beta thalassemia

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4779508

Acute iron overload and oxidative stress in brain

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4779508

Comment on: The Protective Role of Silymarin and Deferoxamine Against Iron Dextran-Induced Renal Iron Deposition in Male Rats

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4779508

Antiosteoclastic activity of milk thistle extract after ovariectomy to suppress estrogen deficiency-induced osteoporosis

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4779508

The incidence of hepatitis C in patients with thalassemia after screening in blood transfusion centers: a fourteen-year study

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4779508

Comparison of the prophylactic effect of silymarin and deferoxamine on iron overload-induced hepatotoxicity in rat.

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4779508

Silymarin, the antioxidant component and Silybum marianum extracts prevent liver damage

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4779508

Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4779508

Prevalence of β-Thalassemia and hemoglobin E in two migrant populations of Manipur, North East India.

31 May 2018

1 reference

https://api.crossref.org/works/10.1155/2016/3046373

Immunomodulatory effects of silymarin in patients with β-thalassemia major.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155/2016/3046373

Combined therapy of silymarin and desferrioxamine in patients with beta-thalassemia major: a randomized double-blind clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155/2016/3046373

The effect of an iron (III) chelator, silybin, on the proliferation and cell cycle of Jurkat cells: a comparison with desferrioxamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1155/2016/3046373

Silybin, a new iron-chelating agent.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155/2016/3046373

Silybin treatment is associated with reduction in serum ferritin in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155/2016/3046373

Double-faced cell-mediated immunity in beta-thalassemia major: stimulated phenotype versus suppressed activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1155/2016/3046373

Silibinin protects mice from T cell-dependent liver injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1155/2016/3046373

Silibinin promotes osteoblast differentiation of human bone marrow stromal cells via bone morphogenetic protein signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1155/2016/3046373

Silymarin is a selective estrogen receptor beta (ERbeta) agonist and has estrogenic effects in the metaphysis of the femur but no or antiestrogenic effects in the uterus of ovariectomized (ovx) rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155/2016/3046373

Renal dysfunction in patients with beta-thalassemia major receiving iron chelation therapy either with deferoxamine and deferiprone or with deferasirox

21 January 2018

1 reference

https://api.crossref.org/works/10.1155/2016/3046373

Dietary supplementation of silymarin protects against chemically induced nephrotoxicity, inflammation and renal tumor promotion response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155/2016/3046373

Effect of silymarin on streptozotocin-nicotinamide-induced type 2 diabetic nephropathy in rats.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4779508

Survival of Thalassemic Patients Referred to the Boo Ali Sina Teaching Hospital, Sari, Iran

28 November 2018

1 reference

https://api.crossref.org/works/10.1155/2016/3046373

Effect of addition of silymarin to renin-angiotensin system inhibitors on proteinuria in type 2 diabetic patients with overt nephropathy: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

12 December 2020

Increased Oxidative Stress and Iron Overload in Jordanian β-Thalassemic Children

1 reference

12 December 2020

Comparison of organ dysfunction in transfused patients with SCD or beta thalassemia

1 reference

12 December 2020

Tumor necrosis factor-alpha in gestation and puerperium of women with gestational hypertension and pre-eclampsia

1 reference

12 December 2020

Effects of silymarin on the proliferation and glutathione levels of peripheral blood mononuclear cells from beta-thalassemia major patients

1 reference

12 December 2020

Osteogenic activity of silymarin through enhancement of alkaline phosphatase and osteocalcin in osteoblasts and tibia-fractured mice

1 reference

12 December 2020

Immunostimulatory effect of Silybum Marianum (milk thistle) extract

1 reference

12 December 2020

Immunological status of thalassemia syndrome

1 reference

12 December 2020

Serum levels of TGFβ, IL-10, IL-17, and IL-23 cytokines in β-thalassemia major patients: the impact of silymarin therapy

1 reference

12 December 2020

Effect of transfusional iron overload on immune response

1 reference

12 December 2020

A randomized double-blind, placebo-controlled study of therapeutic effects of silymarin in β-thalassemia major patients receiving desferrioxamine

1 reference

12 December 2020

Influence of silymarin and its flavonolignans on H(2)O(2)-induced oxidative stress in human keratinocytes and mouse fibroblasts

1 reference

12 December 2020

Silibinin protects against isoproterenol-induced rat cardiac myocyte injury through mitochondrial pathway after up-regulation of SIRT1

1 reference

12 December 2020

The role of iron overload on oxidative stress in sickle cell anemia

1 reference

12 December 2020

Identifiers

DOI

10.1155/2016/3046373

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26997953 AND SRC:MED&resulttype=core&format=json

12 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26997953 AND SRC:MED&resulttype=core&format=json

12 March 2020

PubMed publication ID

26997953

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26997953 AND SRC:MED&resulttype=core&format=json